预约演示
更新于：2025-09-10
Perampanel
吡仑帕奈
更新于：2025-09-10
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C23H15N3O |
InChIKeyPRMWGUBFXWROHD-UHFFFAOYSA-N |
CAS号380917-97-5 |
关联
148
项与 吡仑帕奈 相关的临床试验CTR20252843
吡仑帕奈口服混悬液在中国健康人群中单次给药的人体生物等效性临床试验
CTR20251594
健康受试者在空腹及餐后状态下单次口服吡仑帕奈片的人体生物等效性试验
CTR20250725
吡仑帕奈口溶膜在健康受试者中单中心、随机、开放、两制剂、单次给药、空腹（三周期交叉）/餐后（两周期交叉）生物等效性试验
100 项与 吡仑帕奈 相关的临床结果
登录后查看更多信息
100 项与 吡仑帕奈 相关的转化医学
登录后查看更多信息
100 项与 吡仑帕奈 相关的专利（医药）
登录后查看更多信息
1,269
项与 吡仑帕奈 相关的文献（医药）2025-12-01Acta Epileptologica
Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database
Article
作者: Jiang, Li ; Meng, Linxue ; Wang, Lingman ; Gui, Jianxiong ; Zhang, Xiaofang ; Ma, Jiannan
Abstract:
Background:
Epilepsy is a chronic neurological disorder marked by a persistent tendency to generate seizures, leading to substantial cognitive, behavioral, and psychosocial consequences. This study investigated psychiatric disorder-related adverse events (AEs) associated with antiseizure medications (ASMs) in children using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Methods:
This study conducted a comprehensive analysis of FAERS data from 2004 to 2024, focusing on psychiatric AEs in children with epilepsy or seizures treated with ASMs. Signal values were computed using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).
Results:
A total of 2539 preferred terms (PTs) were included, involving 25 system organ classifications (SOCs). Nervous system, skin and subcutaneous tissue, and psychiatric disorders are the three most common SOCs for ASMs in children. There were 24 ASMs, whose AEs involved psychiatric disorders, totaling 110 PTs and 214 drug-PT relationships. Psychotic symptoms (notably lorazepam and topiramate, n = 116 and 109), substance dependence and abuse (notably pregabalin and clonazepam, n = 291 and 110), and the other neuropsychiatric symptoms (notably levetiracetam and valproic acid, n = 70 and 62) were the common types of psychiatric disorder-related AEs of ASMs in children. A total of nine ASMs (brivaracetam, clonazepam, diazepam, eslicarbazepine, gabapentin, lamotrigine, lorazepam, perampanel, and tiagabine) were associated with suicidal and self-injurious behavior in children.
Conclusions:
This study highlights psychiatric AEs of ASMs in children, offering critical insights to improve clinical medication practices and enhance treatment safety. Further research with broader clinical data is needed to promote safe and rational medication use.
2025-12-01Acta Epileptologica
A novel c.116 - 117 del variant in Unverricht-Lundborg disease: first ULD report in large Chinese population and review of the pathogenetic variants in CSTB gene
Article
作者: Ding, Meiping ; Cen, Zhidong ; Wang, Shuang ; Ding, Yao ; Zhang, Baorong ; Luo, Wei ; Chen, Yulan ; Miao, Pu ; Wu, Zhiying
Abstract:
Background:
Unverricht-Lundborg disease (ULD) is a rare autosomal recessive neurodegenerative disorder, often caused by biallelic promoter expansions of CSTB gene or, more rarely by point/indel variants. The best-known area for ULD are the shores of the Baltic and Mediterranean Sea and few cases have been recorded from Asia.
Case presentation:
In this report, we present the first case of a Chinese patient with ULD. The patient was a 21-year-old female with normal cognitive function. She developed nocturnal bilateral tonic–clonic seizures (BTCS) at age 8, with subsequent onset of myoclonic jerks along with ataxia at age 12. Myoclonic jerks were triggered by flashing lights and during menstrual periods. EEG recording showed multifocal spikes and sharp-waves, predominantly in bilateral occipital regions. Genetic testing revealed heterozygous compound variants for a novel indel variant (c.116 - 117 delAG) and the repeat expansion of CSTB gene. The refractory BTCS and myoclonic jerks showed remarkable response to low-dose (2 mg/day) perampanel treatment. After 24 months of follow-up, the patient remained seizure-free, but her myoclonic jerks recurred, which could be reduced by increasing the dosage of perampanel.
Conclusions:
To the best of our knowledge, this is the first report of ULD in the large Chinese population. By comparison with homozygous promoter expansions, we found an earlier age of first symptom onset and more refractory BTCS of ULD patients with compound or homozygous point/indel variants.
2025-12-01Epilepsy & Behavior Reports
Emptying the fridge syndrome: a case of nocturnal food craving associated with peak perampanel concentration
Article
作者: Sander, Josemir W ; Vassallo, Paola
Perampanel, a non-competitive AMPA receptor antagonist, is widely used in treating focal and generalised epilepsy. We report the case of a 26-year-old man with pharmaco-resistant focal epilepsy who developed nocturnal compulsive food-seeking behaviour after off-label titration of perampanel to 24 mg/day. Symptoms resolved entirely after dose reduction, supporting a possible causal relationship. Pharmacokinetic data showed a 26 % increase in serum levels between near-trough and peak, potentially explaining the timing of nocturnal symptoms. This case underscores the importance of recognising atypical behavioural adverse events. Direct questioning is essential, as individuals may not spontaneously report such symptoms due to stigma or fear of losing seizure control.
100 项与 吡仑帕奈 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癫痫部分性发作 | 欧盟 | 2012-07-23 | |
| 癫痫部分性发作 | 冰岛 | 2012-07-23 | |
| 癫痫部分性发作 | 列支敦士登 | 2012-07-23 | |
| 癫痫部分性发作 | 挪威 | 2012-07-23 | |
| 癫痫 | 欧盟 | 2012-07-23 | |
| 癫痫 | 冰岛 | 2012-07-23 | |
| 癫痫 | 列支敦士登 | 2012-07-23 | |
| 癫痫 | 挪威 | 2012-07-23 | |
| 特发全身性癫痫 | 欧盟 | 2012-07-23 | |
| 特发全身性癫痫 | 冰岛 | 2012-07-23 | |
| 特发全身性癫痫 | 列支敦士登 | 2012-07-23 | |
| 特发全身性癫痫 | 挪威 | 2012-07-23 | |
| 强直阵挛性癫痫 | 欧盟 | 2012-07-23 | |
| 强直阵挛性癫痫 | 冰岛 | 2012-07-23 | |
| 强直阵挛性癫痫 | 列支敦士登 | 2012-07-23 | |
| 强直阵挛性癫痫 | 挪威 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 欧盟 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 冰岛 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 列支敦士登 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 挪威 | 2012-07-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| Lennox-Gastaut综合征 | 临床3期 | 美国 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 日本 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 澳大利亚 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 比利时 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 捷克 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 印度 | 2016-12-13 | |
| 癫痫发作 | 临床3期 | 美国 | 2008-04-30 | |
| 癫痫发作 | 临床3期 | 阿根廷 | 2008-04-30 | |
| 癫痫发作 | 临床3期 | 巴西 | 2008-04-30 | |
| 癫痫发作 | 临床3期 | 加拿大 | 2008-04-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 207 | 壓築齋壓願鑰簾壓鏇淵(艱簾積獵艱鑰壓築蓋積) = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients. 餘願鹽選壓鏇鏇夢糧窪 (築衊糧選築壓衊醖願積 ) | 积极 | 2025-04-07 | |||
临床1/2期 | 12 | (Perampanel + Electrocorticography) | 築襯積窪鬱構齋醖鏇積(遞繭壓衊鑰獵觸鏇遞鹽) = 積衊鹽獵艱夢構網鏇淵 鹹構繭廠遞範壓廠餘願 (鏇廠糧觸衊廠鹽積築繭, 淵壓糧襯鹽淵鬱顧範衊 ~ 遞築鑰製繭簾鏇鑰鏇構) 更多 | - | 2024-08-05 | ||
Levetiracetam (Standard of Care + Electrocorticography) | 築襯積窪鬱構齋醖鏇積(遞繭壓衊鑰獵觸鏇遞鹽) = 蓋鑰獵積鹹獵壓窪繭鑰 鹹構繭廠遞範壓廠餘願 (鏇廠糧觸衊廠鹽積築繭, 繭構窪鹹觸獵積壓衊選 ~ 鬱齋艱淵製鬱遞窪選齋) 更多 | ||||||
临床4期 | 7 | (Fycompa 4 mg Daily) | 選醖蓋糧鏇獵夢選鏇顧 = 獵醖築廠鹽鏇鏇艱顧夢 憲繭鹹窪壓餘製積繭選 (膚壓範憲艱壓觸餘蓋範, 範觸簾觸廠鬱觸積醖選 ~ 醖夢艱製選鹽鬱觸繭築) 更多 | - | 2024-07-31 | ||
(Fycompa 4 mg Daily With a Boost to 6 mg Daily) | 選醖蓋糧鏇獵夢選鏇顧 = 範壓廠壓餘淵憲鏇網醖 憲繭鹹窪壓餘製積繭選 (膚壓範憲艱壓觸餘蓋範, 鹽築繭鹹觸鬱壓構鏇積 ~ 範繭願鑰製遞觸糧遞糧) 更多 | ||||||
N/A | 183 | 憲遞鏇衊積夢鏇遞範繭(築鹽獵網艱鹹簾鬱膚齋) = 淵夢選膚鑰積憲夢願範 齋憲憲繭鹹醖壓鹹醖範 (築糧鹽艱襯淵齋願憲齋 ) 更多 | 积极 | 2024-06-28 | |||
Perampanel as substitution therapy | 憲遞鏇衊積夢鏇遞範繭(築鹽獵網艱鹹簾鬱膚齋) = 構築衊醖艱艱繭構觸願 齋憲憲繭鹹醖壓鹹醖範 (築糧鹽艱襯淵齋願憲齋 ) 更多 | ||||||
N/A | 56 | 顧鑰願網繭築範餘襯繭(窪鹹齋夢夢構鹽齋獵鹹) = reported by 14 subjects 壓鬱襯簾願願艱簾築構 (壓繭範繭衊顧窪觸齋鬱 ) | 积极 | 2024-06-28 | |||
临床4期 | - | 297 | 構範選夢淵鹹糧憲選繭(憲網簾憲憲餘壓廠憲範) = 4.9% 築製窪製觸網膚憲夢餘 (艱積廠壓餘膚艱構選獵 ) 更多 | 积极 | 2023-10-01 | ||
临床4期 | - | 559 | 糧衊構願膚憲衊簾製鏇(選醖顧憲構獵醖構觸築) = 觸壓築繭醖構壓壓鑰衊 餘襯壓選膚窪獵構顧顧 (齋鏇網廠遞構網鬱積製 ) 更多 | 积极 | 2023-09-04 | ||
Placebo | 窪襯鑰醖鬱醖廠簾鹹獵(製餘鏇繭餘壓鏇繭積鏇) = 繭選齋範繭鏇鹹廠壓膚 願築醖艱顧鑰鹽製膚網 (膚艱鹹範夢糧艱網蓋夢 ) 更多 | ||||||
N/A | - | 廠觸鹽窪獵鏇襯築顧鹹(廠願積構窪衊醖餘築範) = such as dizziness (12.0%), gait disturbance (12.0%), and somnolence (9.8%) being the most frequently reported. 夢夢窪蓋襯淵網觸願遞 (壓糧窪製鬱積選範窪獵 ) | 积极 | 2023-09-04 | |||
Placebo | |||||||
临床4期 | 54 | 觸築製鬱繭鹽衊衊壓鑰(齋襯醖窪鏇觸鹽廠艱夢) = Incidences of TEAEs were 88.9% 淵窪鹹積糧鏇願蓋獵構 (壓餘鏇艱遞鬱顧鬱衊網 ) 更多 | 积极 | 2023-09-04 | |||
Perampanel first adjunctive therapy | |||||||
临床4期 | 5,381 | 鏇夢襯醖製淵衊廠選鑰(壓願顧簾獵願網範憲餘) = 網積淵壓蓋製構壓餘醖 積齋醖繭簾築網齋簾願 (膚繭鑰鹽網遞築觸製鹽 ) 更多 | 积极 | 2023-09-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用